Jersey City-based Organon & Co. on Monday announced it entered into a definitive agreement to be acquired by Sun Pharmaceutical Industries Limited in an all-cash deal valued at an enterprise level of $11.75 billion.
Under the terms of the agreement, Organon stockholders will receive $14.00 per share in cash, representing a significant milestone for the company that first established its headquarters in Jersey City following its spinoff from Rahway-based Merck (known as MSD outside the U.S. and Canada) in 2021.
Since its inception, Organon has leveraged New Jersey’s deep life sciences talent pool to become a global leader in women’s health. The company currently manages a portfolio of more than 70 products, including biosimilars and general medicines, commercialized across 140 countries.
The acquisition by Sun Pharma—the largest pharmaceutical company in India—is designed to marry Organon’s extensive global reach and specialized women’s health portfolio with Sun Pharma’s innovative and specialty generic pipeline.
“We believe Sun Pharma is well positioned to support Organon’s businesses, employees, and patients globally, and to further advance our commitment to delivering impactful medicines,” Carrie Cox, Executive Chair of Organon said.
The merger is expected to propel the combined entity into the top 25 global pharmaceutical companies, with a projected combined revenue of $12.4 billion.
For New Jersey, the deal underscores the state’s continued status as a critical hub for international M&A activity in the health care sector. Key strategic outcomes of the merger include:
- Women’s Health Leadership: The combined company will rank as a Top 3 global player in Women’s Health.
- Biosimilar Growth: Sun Pharma will enter the biosimilars market as a Top 10 global provider.
- Innovative Shift: The entity will see a significant shift toward innovative medicines, which will account for roughly 27% of total revenue.
While the headquarters of the parent company remains in Mumbai, Sun Pharma leadership emphasized the value of the New Jersey-based team. Kirti Ganorkar, Managing Director of Sun Pharma, noted that “responsible value creation” and “leveraging Organon’s talent pool” are immediate priorities during the integration phase.
The transaction, which has been approved by the boards of both companies, is expected to close in early 2027. It remains subject to customary closing conditions, including regulatory hurdles and the approval of Organon stockholders.
Upon completion, Organon will survive the merger as a subsidiary of Sun Pharma, ensuring that its legacy of advancing access and affordability in women’s health continues under a massive new global umbrella.
